Last reviewed · How we verify
Voltaren Topical Gel
At a glance
| Generic name | Voltaren Topical Gel |
|---|---|
| Also known as | diclofenac emulgel, diclofenac diethylamine |
| Sponsor | University of Calgary |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Home-Based Strategies for Knee Osteoarthritis (NA)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days. (PHASE1)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
- Effects of Exercise Versus Topical Agents on Knee Osteoarthritis (NA)
- Exercise vs. Topical Diclofenac vs. PRP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voltaren Topical Gel CI brief — competitive landscape report
- Voltaren Topical Gel updates RSS · CI watch RSS
- University of Calgary portfolio CI